Rate Control in Atrial Fibrillation II

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

Also called NCT02695992

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Asker & Baerum Hospital (from the registry)
Registry
  • NCT NCT02695992
  • EudraCT 2015-001918-98
Other papers using this trial's data
  • Effects of diltiazem and metoprolol on levels of high-sensitivity troponin I in patients with permanent atrial fibrillation: a randomized trial BMC cardiovascular disorders, 2025-03-14 DOI, PubMed 40087560, PMC11907844 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02695992. Randomized; single masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2021-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rate Control in Atrial Fibrillation II
Acronym
RATAFII
Condition
Permanent Atrial Fibrillation
Intervention (Drug)
Metoprolol
Intervention (Drug)
Diltiazem
Lead sponsor
Asker & Baerum Hospital (class: other)
Collaborator
Vestre Viken Hospital Trust (class: other)
Collaborator
Helse Sor-Ost (class: other government)

Record details

Record id
cardio:ct-nct02695992
Content hash
34ccdaf7983f9b125ae368d8bb2fe6d1e1ce1e085a017da47247176304855409